Pegargiminase - Polaris Pharmaceuticals

Drug Profile

Pegargiminase - Polaris Pharmaceuticals

Alternative Names: ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Peglyated arginine deiminase - Phoenix Pharmacologics; Pegylated arginine deiminase - Polaris Group

Latest Information Update: 14 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Barts and The London School of Medicine and Dentistry; Polaris Pharmaceuticals; University of Miami; Washington University School of Medicine
  • Class Antineoplastics; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
  • Mechanism of Action Arginine deiminase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Mesothelioma; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Liver cancer
  • Phase II/III Mesothelioma
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Non-Hodgkin's lymphoma; Small cell lung cancer; Soft tissue sarcoma
  • Phase I Gastrointestinal cancer; Pancreatic cancer; Solid tumours
  • Preclinical Sarcoma
  • No development reported Bladder cancer; Breast cancer; Cancer; Glioblastoma; Lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Viral infections

Most Recent Events

  • 14 Aug 2018 Polaris completes a phase I trial in Pancreatic cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA before August 2018 (NCT02101580) (Polaris pipeline, August 2018)
  • 26 Jun 2018 Efficacy and adverse events data from a phase Ib trial in Soild tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top